Cibc World Markets Corp Makes New $1.07 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Cibc World Markets Corp purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,532 shares of the medical research company’s stock, valued at approximately $1,065,000.

Other hedge funds also recently bought and sold shares of the company. Ardevora Asset Management LLP boosted its holdings in shares of Bio-Rad Laboratories by 9.5% during the fourth quarter. Ardevora Asset Management LLP now owns 114,147 shares of the medical research company’s stock worth $47,998,000 after purchasing an additional 9,918 shares during the last quarter. MML Investors Services LLC boosted its holdings in shares of Bio-Rad Laboratories by 13.5% during the third quarter. MML Investors Services LLC now owns 7,959 shares of the medical research company’s stock worth $3,320,000 after purchasing an additional 944 shares during the last quarter. Guggenheim Capital LLC boosted its holdings in shares of Bio-Rad Laboratories by 18.6% during the third quarter. Guggenheim Capital LLC now owns 1,592 shares of the medical research company’s stock worth $664,000 after purchasing an additional 250 shares during the last quarter. FORA Capital LLC boosted its holdings in shares of Bio-Rad Laboratories by 34.2% during the fourth quarter. FORA Capital LLC now owns 1,569 shares of the medical research company’s stock worth $660,000 after purchasing an additional 400 shares during the last quarter. Finally, Aigen Investment Management LP boosted its holdings in shares of Bio-Rad Laboratories by 49.8% during the third quarter. Aigen Investment Management LP now owns 713 shares of the medical research company’s stock worth $297,000 after purchasing an additional 237 shares during the last quarter. Hedge funds and other institutional investors own 64.35% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.5 %

NYSE:BIO opened at $382.14 on Monday. The business’s 50-day moving average is $447.80 and its two-hundred day moving average is $442.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.56 and a quick ratio of 4.28. Bio-Rad Laboratories, Inc. has a 12 month low of $344.63 and a 12 month high of $572.70. The firm has a market capitalization of $11.32 billion, a PE ratio of -58.43 and a beta of 0.91.

Bio-Rad Laboratories (NYSE:BIO – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The medical research company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.24 by $0.10. Bio-Rad Laboratories had a positive return on equity of 4.10% and a negative net margin of 7.01%. The company had revenue of $676.80 million for the quarter, compared to analyst estimates of $689.28 million. During the same period last year, the company posted $4.94 earnings per share. The firm’s revenue was down 3.3% compared to the same quarter last year. Research analysts predict that Bio-Rad Laboratories, Inc. will post 14.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Timothy S. Ernst sold 1,746 shares of the business’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total value of $849,306.78. Following the transaction, the executive vice president now owns 2,671 shares in the company, valued at $1,299,254.53. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 17.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BIO shares. StockNews.com assumed coverage on Bio-Rad Laboratories in a report on Thursday. They set a “buy” rating on the stock. TheStreet upgraded Bio-Rad Laboratories from a “d+” rating to a “c” rating in a report on Thursday, February 16th. Royal Bank of Canada lifted their target price on Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Finally, Credit Suisse Group lifted their target price on Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $653.00.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.